Travere Therapeutics (TVTX) Non Operating Income (2013 - 2026)

Travere Therapeutics has reported Non Operating Income for 14 years, with the latest figure at -$91000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 106.12% year-over-year to -$91000.0; the trailing twelve-month figure through Mar 2026 stood at $11.7 million (up 775.11% YoY), and the FY2025 full-year result was $13.6 million, up 308.53% from the prior year.
• Non Operating Income for Q1 2026 stood at -$91000.0, down from $11.4 million in the prior quarter.
• The five-year high for Non Operating Income was $11.4 million in Q4 2025, with the low at -$9.8 million in Q1 2022.
• Historically, Non Operating Income has averaged $549117.6 across 5 years, with a median of $397000.0 in 2024.
• The largest YoY upside for Non Operating Income was 3888.51% in 2024 against a maximum downside of 826.87% in 2024.
• Travere Therapeutics' Non Operating Income stood at $872000.0 in 2022, then jumped by 57.57% to $1.4 million in 2023, then sank by 71.11% to $397000.0 in 2024, then surged by 2762.22% to $11.4 million in 2025, then slumped by 100.8% to -$91000.0 in 2026.
• The last three Non Operating Income figures came in at -$91000.0 (Q1 2026), $11.4 million (Q4 2025), and $487000.0 (Q3 2025), per Business Quant data.